NASDAQ$TNXP

Tonix Pharmaceuticals Holding Corp · Q1 2025 earnings

Q1 2025 earnings · · After market close · Investor relations

Briefing

Tonix Pharmaceuticals reported Q1 2025 a net loss of $16.8M, diluted EPS of $(2.84).

For Q1 2025, Tonix Pharmaceuticals reported net loss was $16.8M, diluted EPS was $-2.84. Management discusses operating trends, liquidity, and outlook in the quarterly filing.

  • Net loss $16.8M.
  • Diluted EPS $-2.84.
  • MD&A highlights operating priorities, liquidity, and sector-specific risks.

Headline financials

Total Revenue

$2.43M

Previous: $2.48M-2.1%
EPS (adj)

-$2.84

Previous: -$0.18-1477.8%
R&D Expenses

$7.44M

No prior period
G&A Expenses

$10.1M

No prior period
Net Cash Used Ops

$16.6M

No prior period
Capital Expenditures

-$6K

Previous: -$108K+94.4%
Net Income

-$16.8M

Previous: -$14.9M-12.7%
Operating Income

-$16.1M

Previous: -$21.4M+24.8%

Revenue & EPS history

Tonix · Revenue · Quarterly

$2.43M

Q1 2025-2.1%vs Q1 2024
Beat estimate in 2 of 9 quarters(22%)
ActualEstimate

Forward guidance

Management emphasizes path to profitability, liquidity, and cost discipline.

Tailwinds

  • Operating initiatives and partnership milestones.
  • Cash runway and restructuring where applicable.

Headwinds

  • Operating losses and financing needs.
  • Macro and competitive uncertainty.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q1 2025

Historical avgQ1 2025

-1.2%

Avg return

Earnings day

+0.5%

Avg return

5 days after

-12.7%

Avg return

30 days after

44%

23 / 52 earnings

Positive

+12.9%

Q1 2016

Best reaction

-31.7%

Q1 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.1%+11.7%
Q4 2025+0.0%+19.1%-2.0%
Q3 2025-0.9%-6.5%+16.2%
Q1 2025+5.2%+45.9%+80.0%
Q4 2024-2.4%+48.6%-23.5%
Q3 2024+0.6%-7.1%+64.3%
Q2 2024-2.6%-21.7%-65.2%
Q1 2024+4.8%+17.6%-79.6%
Q4 2023+2.5%-10.5%-5.3%
Q3 2023-4.3%-6.1%-18.4%
Q2 2023+1.8%+1.1%-4.2%
Q1 2023-31.7%-40.6%-41.2%
Q4 2022+8.7%-3.2%-9.7%
Q3 2022+1.5%+4.4%-17.8%
Q2 2022-11.4%-11.4%-42.4%
Q1 2022-5.4%-7.1%-49.3%
Q4 2021-4.7%+9.1%-13.6%
Q3 2021+7.4%-1.8%-18.2%
Q2 2021+12.5%-1.4%-2.9%
Q1 2021-2.8%+0.0%+22.6%
Q4 2020+0.0%+14.2%-14.2%
Q3 2020-1.8%+10.7%+16.1%
Q2 2020-12.1%-12.1%-30.2%
Q1 2020-3.3%-2.8%-4.2%
Q4 2019-13.2%-14.1%-20.0%
Q3 2019-3.1%+0.8%-59.5%
Q2 2019+0.5%+0.0%+4.3%
Q1 2019-9.5%-18.0%-21.0%
Q4 2018-8.7%-19.4%-15.6%
Q3 2018-10.6%-18.5%-54.8%
Q2 2018-2.9%+15.2%-21.0%
Q1 2018+6.2%+11.6%+48.6%
Q4 2017-4.7%-1.1%-13.4%
Q3 2017-7.9%-2.2%+3.3%
Q1 2017+0.5%+4.9%+3.4%
Q4 2016-12.5%-10.9%-15.0%
Q3 2016+1.3%-4.5%-6.8%
Q2 2016+9.7%+23.7%-58.0%
Q1 2016+12.9%
Q4 2015-0.2%
Q3 2015-6.2%
Q2 2015+1.2%
Q1 2015+1.8%
Q4 2014+7.9%
Q3 2014-2.5%
Q2 2014+12.4%
Q1 2014-1.7%
Q4 2013+11.2%
Q3 2013+0.5%
Q2 2013
Q1 2013
Q3 2012
Q2 2012+4.7%
Q1 2012-12.0%
Q4 2012+0.0%
Q3 2011
Q2 2011
Q1 2011
Q4 2010
Q3 2009
Q2 2010
Q1 2010

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro